Mutant IDH1 Downregulates ATM and Alters DNA Repair and Sensitivity to DNA Damage Independent of TET2.

Mutations in the isocitrate dehydrogenase-1 gene (IDH1) are common drivers of acute myeloid leukemia (AML) but their mechanism is not fully understood. It is thought that IDH1 mutants act by inhibiting TET2 to alter DNA methylation, but there are significant unexplained clinical differences between IDH1- and TET2-mutant diseases. We have discovered that mice expressing endogenous mutant IDH1 have reduced numbers of hematopoietic stem cells (HSCs), in contrast to Tet2 knockout (TET2-KO) mice. Mutant IDH1 downregulates the DNA damage (DD) sensor ATM by altering histone methylation, leading to impaired DNA repair, increased sensitivity to DD, and reduced HSC self-renewal, independent of TET2. ATM expression is also decreased in human IDH1-mutated AML. These findings may have implications for treatment of IDH-mutant leukemia.

[1]  Y. Ikeda,et al.  Tet2 disruption leads to enhanced self-renewal and altered differentiation of fetal liver hematopoietic stem cells , 2012, Scientific Reports.

[2]  J. Licht,et al.  Leukemic IDH1 and IDH2 mutations result in a hypermethylation phenotype, disrupt TET2 function, and impair hematopoietic differentiation. , 2010, Cancer cell.

[3]  H. Satoh,et al.  Regulation of Reactive Oxygen Species by Atm Is Essential for Proper Response to DNA Double-Strand Breaks in Lymphocytes1 , 2007, The Journal of Immunology.

[4]  M. Carroll,et al.  DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies , 2014, Leukemia.

[5]  I. Weissman,et al.  Quiescent hematopoietic stem cells accumulate DNA damage during aging that is repaired upon entry into cell cycle. , 2014, Cell stem cell.

[6]  P. Opolon,et al.  TET2 inactivation results in pleiotropic hematopoietic abnormalities in mouse and is a recurrent event during human lymphomagenesis. , 2011, Cancer cell.

[7]  T. Mak,et al.  Oncogenic isocitrate dehydrogenase mutations: mechanisms, models, and clinical opportunities. , 2013, Cancer discovery.

[8]  B. Smith,et al.  DNMT3A and IDH mutations in acute myeloid leukemia and other myeloid malignancies: associations with prognosis and potential treatment strategies , 2015, Leukemia.

[9]  Tak W. Mak,et al.  Mule/Huwe1/Arf-BP1 suppresses Ras-driven tumorigenesis by preventing c-Myc/Miz1-mediated down-regulation of p21 and p15. , 2013, Genes & development.

[10]  S. Lowe,et al.  Cancer-associated IDH2 mutants drive an acute myeloid leukemia that is susceptible to Brd4 inhibition , 2013, Genes & development.

[11]  O. Abdel-Wahab,et al.  Tet2 loss leads to increased hematopoietic stem cell self-renewal and myeloid transformation. , 2011, Cancer cell.

[12]  I. Weissman,et al.  Preleukemic mutations in human acute myeloid leukemia affect epigenetic regulators and persist in remission , 2014, Proceedings of the National Academy of Sciences.

[13]  T. Stracker,et al.  The ATM signaling network in development and disease , 2013, Front. Genet..

[14]  Irving L. Weissman,et al.  Deficiencies in DNA damage repair limit the function of haematopoietic stem cells with age , 2007, Nature.

[15]  Mithat Gonen,et al.  Recurrent Somatic TET2 Mutations in Normal Elderly Individuals With Clonal Hematopoiesis , 2012, Nature Genetics.

[16]  G. Mills,et al.  Genome-wide Transcriptome Profiling of Homologous Recombination DNA Repair , 2014, Nature Communications.

[17]  Joshua F. McMichael,et al.  The Origin and Evolution of Mutations in Acute Myeloid Leukemia , 2012, Cell.

[18]  K. Rajewsky,et al.  Ten-Eleven-Translocation 2 (TET2) negatively regulates homeostasis and differentiation of hematopoietic stem cells in mice , 2011, Proceedings of the National Academy of Sciences.

[19]  L. Niedernhofer.  DNA repair is crucial for maintaining hematopoietic stem cell function. , 2008, DNA repair.

[20]  T. Suda,et al.  Telomerase reverse transcriptase protects ATM-deficient hematopoietic stem cells from ROS-induced apoptosis through a telomere-independent mechanism. , 2011, Blood.

[21]  B. Alman,et al.  Mutant IDH is sufficient to initiate enchondromatosis in mice , 2015, Proceedings of the National Academy of Sciences.

[22]  Howard Y. Chang,et al.  Transposition of native chromatin for fast and sensitive epigenomic profiling of open chromatin, DNA-binding proteins and nucleosome position , 2013, Nature Methods.

[23]  S. Inoue,et al.  D-2-hydroxyglutarate produced by mutant IDH1 perturbs collagen maturation and basement membrane function. , 2012, Genes & development.

[24]  N. Socci,et al.  Prognostic relevance of integrated genetic profiling in acute myeloid leukemia. , 2012, The New England journal of medicine.

[25]  Benjamin J. Raphael,et al.  Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. , 2013, The New England journal of medicine.

[26]  O. Abdel-Wahab,et al.  The role of mutations in epigenetic regulators in myeloid malignancies , 2012, Nature Reviews Cancer.

[27]  Stephan Beck,et al.  Methylome analysis using MeDIP-seq with low DNA concentrations , 2012, Nature Protocols.

[28]  Junjie Chen,et al.  Gemcitabine-Induced Activation of Checkpoint Signaling Pathways That Affect Tumor Cell Survival , 2005, Molecular Pharmacology.

[29]  Zhigang Zhao,et al.  Combined Loss of Tet1 and Tet2 Promotes B Cell, but Not Myeloid Malignancies, in Mice. , 2015, Cell reports.

[30]  M. Takagi,et al.  ATM-dependent DNA damage-response pathway as a determinant in chronic myelogenous leukemia. , 2013, DNA repair.

[31]  G. Reifenberger,et al.  IDH1(R132H) mutation increases murine haematopoietic progenitors and alters epigenetics , 2012, Nature.

[32]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[33]  D. Purdie,et al.  Mice heterozygous for mutation in Atm, the gene involved in ataxia-telangiectasia, have heightened susceptibility to cancer , 2002, Nature Genetics.

[34]  R. Jaenisch,et al.  TET1 is a tumor suppressor of hematopoietic malignancy , 2015, Nature Immunology.

[35]  S. Berger,et al.  IDH mutation impairs histone demethylation and results in a block to cell differentiation , 2012, Nature.

[36]  A. Rao,et al.  Acute loss of TET function results in aggressive myeloid cancer in mice , 2015, Nature Communications.

[37]  Scott A. Armstrong,et al.  DNA-damage-induced differentiation of leukaemic cells as an anti-cancer barrier , 2014, Nature.

[38]  R. Klose,et al.  The oncometabolite 2‐hydroxyglutarate inhibits histone lysine demethylases , 2011, EMBO reports.

[39]  Thomas J. Hudson,et al.  Corrigendum: Identification of pre-leukaemic haematopoietic stem cells in acute leukaemia , 2014, Nature.

[40]  M. Warr,et al.  Hematopoietic stem cell quiescence promotes error-prone DNA repair and mutagenesis. , 2010, Cell stem cell.

[41]  Anastasia Nijnik,et al.  DNA repair is limiting for haematopoietic stem cells during ageing , 2007, Nature.

[42]  K. Miyagawa,et al.  Ataxia Telangiectasia Mutated (ATM)-mediated DNA Damage Response in Oxidative Stress-induced Vascular Endothelial Cell Senescence* , 2010, Journal of Biological Chemistry.

[43]  G. Vassiliou,et al.  Acute myeloid leukaemia: a paradigm for the clonal evolution of cancer? , 2014, Disease Models & Mechanisms.

[44]  J. Krosl,et al.  The methyltransferase G9a regulates HoxA9-dependent transcription in AML , 2014, Genes & development.

[45]  I. Weissman,et al.  Clonal Evolution of Preleukemic Hematopoietic Stem Cells Precedes Human Acute Myeloid Leukemia , 2012, Science Translational Medicine.

[46]  K. J. Patel,et al.  Genotoxic consequences of endogenous aldehydes on mouse haematopoietic stem cell function , 2012, Nature.

[47]  Tak W. Mak,et al.  Regulation of oxidative stress by ATM is required for self-renewal of haematopoietic stem cells , 2004, Nature.

[48]  J. Krosl,et al.  RNAi screen identifies Jarid1b as a major regulator of mouse HSC activity. , 2013, Blood.

[49]  Yulin Chen,et al.  Gadd45a deletion aggravates hematopoietic stem cell dysfunction in ATM-deficient mice , 2014, Protein & Cell.